The University of Miami Sylvester Comprehensive Cancer Center has opened a phase II clinical trial of a monoclonal antibody which offers potential treatment for hematologic malignancies. This antibody, SGN-30, shows promise against several lymphomas by acting as a biological response modifier – a method to help enhance immunity to fight cancer. Several patients are already enrolled in the protocol.
The University of Miami Sylvester Comprehensive Cancer Center has opened a Phase I clinical trial on a potential treatment for slow-growing tumor cells. The treatment has shown great promise in a variety of solid tumors in the laboratory and would be the first of its kind to focus on these hard-to-treat cancer cells, which can also contribute to metastasis. Theodore J. Lampidis, Ph.D., a scientist in the Tumor Cell Biology Program at UM/Sylvester, developed a way to target these slow-growing malignant cells through glycolysis, the process by which a cell converts sugar into energy.
The Department of Pathology at the University of Miami School of Medicine has created a revolutionary new way to test tissue samples so that patients learn the results of cancer biopsies and other surgery in just one hour instead of the next day.